세계의 바이오마커 검사 서비스 시장

Global Biomarker Testing Services Market to Reach US$1.1 Billion by 2030

The global market for Biomarker Testing Services estimated at US$700.5 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Biomarker Assay Development & Validation Service, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$762.6 Million by the end of the analysis period. Growth in the Flow Cytometry Service segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$184.1 Million While China is Forecast to Grow at 7.9% CAGR

The Biomarker Testing Services market in the U.S. is estimated at US$184.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$178.7 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Biomarker Testing Services Market - Key Trends & Drivers Summarized

Why Is Biomarker Testing Gaining Importance in Modern Healthcare?

Biomarker testing has become a cornerstone of precision medicine, enabling early disease detection, treatment monitoring, and patient stratification for targeted therapies. With the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions, the need for reliable biomarker testing services has surged. These services facilitate more accurate diagnosis and treatment selection, ensuring better patient outcomes and reduced healthcare costs. The increasing reliance on biomarker-based diagnostics is also evident in the rapid expansion of personalized medicine. Pharmaceutical companies are integrating biomarker testing into drug development processes to identify patient populations that would benefit most from specific therapies. Additionally, regulatory agencies are mandating biomarker testing for companion diagnostics, ensuring drug efficacy and safety before market approval. As a result, healthcare providers and diagnostic laboratories are increasingly outsourcing biomarker testing services to specialized laboratories with advanced analytical capabilities.

How Are Technological Innovations Enhancing Biomarker Testing Services?

Technological advancements in genomics, proteomics, and bioinformatics are revolutionizing biomarker testing services, making them more precise, cost-effective, and accessible. Next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques have improved the detection of genetic and molecular biomarkers, allowing for earlier disease identification and risk assessment. Additionally, the integration of artificial intelligence (AI) and machine learning in biomarker data analysis is optimizing test accuracy and accelerating result interpretation. The emergence of liquid biopsy techniques is another groundbreaking development in biomarker testing. These minimally invasive tests enable real-time monitoring of disease progression by analyzing circulating tumor DNA (ctDNA) and other biomarkers in blood samples. Furthermore, advancements in multiplex biomarker assays allow for simultaneous testing of multiple biomarkers, reducing time and costs associated with traditional single-marker tests. As healthcare moves toward data-driven decision-making, these innovations are making biomarker testing services an indispensable tool in modern diagnostics and drug development.

What Market Trends Are Driving the Growth of Biomarker Testing Services?

The growing demand for early disease detection and personalized treatment plans is one of the key trends propelling the biomarker testing services market. Healthcare providers and researchers are prioritizing precision diagnostics to tailor treatments to individual patient profiles, leading to increased adoption of biomarker testing across various medical specialties. Oncology remains the largest application area, with biomarker-driven therapies playing a crucial role in immunotherapy, targeted cancer treatments, and chemotherapy response assessment. Another significant trend shaping the market is the rise of decentralized testing models. The shift toward home-based and point-of-care biomarker testing is being fueled by advances in telemedicine and remote patient monitoring technologies. Companies are developing portable biomarker testing kits and wearable biosensors to facilitate real-time health tracking, reducing the need for frequent hospital visits. Moreover, regulatory support for biomarker-driven clinical trials and drug approvals is encouraging pharmaceutical firms to integrate biomarker testing into their development pipelines, further boosting market demand.

What Are the Key Growth Drivers for the Biomarker Testing Services Market?

The growth in the Biomarker Testing Services market is driven by several factors including the rising incidence of chronic diseases, increasing adoption of precision medicine, and rapid technological advancements in biomarker detection methods. The expansion of companion diagnostics, which require biomarker testing for drug approval and patient selection, is further fueling market growth. Additionally, the increasing investment in clinical research and biotechnology innovations is expanding the scope of biomarker testing applications. Pharmaceutical companies are leveraging biomarker testing services to streamline drug development, reduce clinical trial failures, and enhance regulatory compliance. The shift toward non-invasive diagnostic techniques, such as liquid biopsy and multiplex biomarker panels, is also accelerating market expansion. As healthcare systems worldwide focus on improving diagnostic accuracy and treatment efficacy, biomarker testing services are expected to experience sustained growth, transforming the future of disease management and precision medicine.

SCOPE OF STUDY:

The report analyzes the Biomarker Testing Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service (Biomarker Assay Development & Validation Service, Flow Cytometry Service, Other Services); Type (Molecular Biomarkers, Cellular Biomarkers); End-Use (Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use, CROs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 22 Featured) -

• ACM Global Laboratories
• BioAgilytix Labs, LLC
• Biomedica Medizinprodukte GmbH
• Charles River Laboratories, Inc.
• Creative Biolabs
• Discovery Life Sciences
• Frontage Laboratories, Inc.
• Intertek Group Plc
• Laboratory Corporation of America Holdings
• NorthEast BioLab
• Novigenix SA
• Pacific Biolabs
• Randox Laboratories Ltd.
• Raybiotech, Inc.
• Svar Life Science AB

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Biomarker Testing Services - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Expansion of Precision Medicine and Targeted Therapies Throws the Spotlight on Biomarker Testing Services
  • Rising Clinical Demand for Companion Diagnostics Drives Hospital and Lab Adoption of Biomarker Assays
  • Surge in Liquid Biopsy-Based Testing Accelerates Use of Non-Invasive Biomarkers in Clinical Decision-Making
  • OEM Focus on Multi-Gene Panels and Comprehensive Genomic Profiling Spurs Testing Service Innovation
  • Increased Use of Immune Checkpoint and MSI Markers in Oncology Fuels Growth of Specialized Testing Panels
  • Regulatory Approvals for Lab-Developed Tests and IVD Companion Diagnostics Support Market Commercialization
  • Growing Integration of Molecular Pathology and Centralized Lab Services Enhances Biomarker Testing Capacity
  • Expansion of Testing in Neurology, Cardiology, and Infectious Diseases Broadens Clinical Application Landscape
  • Use of AI for Pathology Image-Based Biomarker Detection Strengthens Digital Testing Platforms
  • Rising Demand for Real-Time Monitoring Biomarkers in Chronic Disease Management Propels Market Uptake
  • Growth in Hospital-Acquired Infection Biomarker Testing Supports Rapid Triage and Antibiotic Stewardship
  • OEM Partnerships With Diagnostic Labs Enhance Sample Volume and Data Generation for Longitudinal Studies
  • Development of Point-of-Care and Decentralized Testing Devices Fuels Access to Biomarker Testing in Rural Areas
  • OEM Investment in Harmonized Sample-to-Insight Workflows Improves Testing Efficiency and Clinical Turnaround
  • Expansion of Next-Generation Sequencing and PCR Infrastructure Supports Multiplexed Biomarker Analysis
  • Integration With EHR Systems and AI-Based Reporting Engines Enhances Clinical Decision Support Capabilities
  • Global Rollout of Tumor-Agnostic Therapies Strengthens Role of Genotype-Based Biomarker Testing
  • Demand for Cost-Effective Panel-Based Tests Encourages Adoption in Community Hospitals and Labs
  • Focus on Test Reproducibility and CLIA/CAP Compliance Drives Quality Assurance in Biomarker Testing Services
  • Shift Toward Value-Based Healthcare Models Supports Reimbursement for Outcome-Linked Biomarker Tests
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Biomarker Assay Development & Validation Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 2: World 6-Year Perspective for Biomarker Assay Development & Validation Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 3: World Recent Past, Current & Future Analysis for Flow Cytometry Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 4: World 6-Year Perspective for Flow Cytometry Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World 6-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Molecular Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 8: World 6-Year Perspective for Molecular Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 9: World Recent Past, Current & Future Analysis for Cellular Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 10: World 6-Year Perspective for Cellular Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World 6-Year Perspective for Pharmaceutical & Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 14: World 6-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 15: World Recent Past, Current & Future Analysis for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 16: World 6-Year Perspective for CROs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 17: World Biomarker Testing Services Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Biomarker Testing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Biomarker Testing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 20: USA Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 21: USA 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
  • TABLE 22: USA Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 23: USA 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
  • TABLE 24: USA Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 25: USA 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
• CANADA
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Canada 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
  • TABLE 28: Canada Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 29: Canada 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
  • TABLE 30: Canada Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 31: Canada 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
• JAPAN
  • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 32: Japan Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Japan 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
  • TABLE 34: Japan Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Japan 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
  • TABLE 36: Japan Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Japan 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
• CHINA
  • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 38: China Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: China 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
  • TABLE 40: China Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 41: China 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
  • TABLE 42: China Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 43: China 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
• EUROPE
  • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 44: Europe Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Europe 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
  • TABLE 46: Europe Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Europe 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
  • TABLE 48: Europe Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Europe 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Biomarker Testing Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe 6-Year Perspective for Biomarker Testing Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
• FRANCE
  • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 52: France Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 53: France 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
  • TABLE 54: France Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 55: France 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
  • TABLE 56: France Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: France 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
• GERMANY
  • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 58: Germany Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Germany 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
  • TABLE 60: Germany Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Germany 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Germany 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
• ITALY
  • TABLE 64: Italy Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Italy 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
  • TABLE 66: Italy Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Italy 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Italy 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
• UNITED KINGDOM
  • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 70: UK Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 71: UK 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
  • TABLE 72: UK Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 73: UK 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
  • TABLE 74: UK Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: UK 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 77: Rest of Europe 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
  • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 79: Rest of Europe 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Rest of Europe 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
• ASIA-PACIFIC
  • Biomarker Testing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Asia-Pacific 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
  • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Asia-Pacific 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Biomarker Testing Services by Service - Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Rest of World 6-Year Perspective for Biomarker Testing Services by Service - Percentage Breakdown of Value Sales for Biomarker Assay Development & Validation Service, Flow Cytometry Service and Other Services for the Years 2025 & 2030
  • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Biomarker Testing Services by Type - Molecular Biomarkers and Cellular Biomarkers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Rest of World 6-Year Perspective for Biomarker Testing Services by Type - Percentage Breakdown of Value Sales for Molecular Biomarkers and Cellular Biomarkers for the Years 2025 & 2030
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Biomarker Testing Services by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of World 6-Year Perspective for Biomarker Testing Services by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2025 & 2030

IV. COMPETITION